Description
“Decoding Fatty Liver Disease” explores the growing global challenge of fat accumulation in the liver and its impact on overall health. This session breaks down the causes, risk factors, and early warning signs that often go unnoticed. It highlights the difference between alcoholic and non-alcoholic fatty liver disease, emphasizing how lifestyle, metabolism, and underlying conditions contribute to its development. Participants will gain clarity on diagnosis, prevention, and effective management strategies. By simplifying complex medical concepts, the talk empowers individuals to take proactive steps toward better liver health.
Summary Listen
- Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions, ranging from simple fat accumulation (steatosis) to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and eventually liver failure. The key driver is an imbalance between predisposing genetic factors and environmental influences like a sedentary lifestyle and a Western diet high in saturated fats and processed foods. This leads to increased body fat, particularly visceral obesity, and insulin resistance, which is a central factor in metabolic disorders.
- Early stages of NAFLD and NASH are often asymptomatic or present with vague symptoms like fatigue, making incidental diagnosis the norm. Progression from early fibrosis (F1, F2) to advanced fibrosis (F3, F4) can accelerate the development of cirrhosis and liver-related mortality. Screening is crucial for at-risk individuals, particularly those with type 2 diabetes, obesity, or a family history of liver disease.
- Screening involves liver enzyme tests (AST, ALT), ultrasound, and in some cases, liver biopsy, though the latter is invasive. Non-invasive tests such as proprietary blood tests (enhanced liver fibrosis tests) and simple scores like FIB-4 and NAFLD Fibrosis Score are also used to assess the likelihood of fibrosis. Vibration-controlled transient elastography (FibroScan) is a non-invasive imaging technique that measures liver stiffness and fat content, aiding in staging fibrosis and steatosis.
- Lifestyle modifications are the cornerstone of NAFLD management. Weight loss of 3-10% can reverse NASH and fibrosis. A Mediterranean or vegetarian diet, rich in monounsaturated fats, polyphenols, and fiber, is recommended. Regular aerobic exercise is also vital to reduce hepatic fat. Bariatric surgery can be considered for severely obese patients.
- Pharmacological options include vitamin E and pioglitazone, which target inflammation and insulin resistance. Statins are used to manage cardiovascular risk, a leading cause of mortality in NAFLD patients. Emerging therapies include GLP-1 receptor agonists (like semaglutide and liraglutide) and dual GIP/GLP-1 receptor agonists (like tirzepatide), which promote weight loss and improve liver histology.
- S-adenosylmethionine (SAMe) is a natural supplement that may support liver health by improving methylation, transsulfuration, and glutathione production, though more research is needed. The overall management strategy involves lifestyle modifications, cardiovascular risk reduction, and targeted therapies based on individual patient characteristics and disease stage.
Sample Certificate
About the Speakers
Dr. Ali Choukair
Gastroenterology Specialist, Clemenceau Medical Center, Dubai, UAE
Comments
Comments
You must be logged in to leave a comment.